Cy­to­ki­net­ic­s' come­back at­tempt with sec­ond-gen mus­cle drug is slammed by a PhII fail­ure in ALS

Sev­en­teen months af­ter Cy­to­ki­net­ics’ lead mus­cle drug crashed and burned in a Phase III ALS tri­al, their $CYTK sec­ond-gen at­tempt has now gone down to de­feat in a Phase II tri­al.

This new drug, relde­sem­tiv, has been billed by CEO Robert Blum as a “more po­tent, more pen­e­tra­ble” drug for treat­ing mus­cle wast­ing in pa­tients. While their drug tirasem­tiv strug­gled and failed in treat­ing ALS pa­tients be­cause of the nec­es­sar­i­ly dose-lim­it­ing as­pects of the ther­a­py, he said, relde­sem­tiv would be free to punch in a high­er weight class.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER